Literaturverzeichnis

1 Thun MJ et al. Aspirine use and reduced risk of fatal colon cancer. N Engl J Med 1991;325 : 1593 -1596

2 Giovannucci E et al. Aspirine use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-246

3 Giardello FM et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis . N Engl J Med 1993;328 (18): 1313-1316

4 Labayle D et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastoenterology 1991;101 (3):635-639

5 Celecoxib in oncology research. Clinical trials. Pharmacia Oncology Publication. October 2002.

6 Smith WL et al. Prostaglandin endoperoxide synthase: structure and catalysis. Biochim Biophys Acta 1991;1083:1 -17

7 Dempke W. et al. Cyclooxygenase-2: a novel target for cancer chemotherapy ? J Cancer Res Clin Oncol 2001;127:411-417

8 Denkert et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002;160 (3):893-903

9 Smith WL et al. Prostaglandin and Thromboxan biosynthesis. Pharm Ther 1991;49:153 -179

10 Tjandrawinata RR et al. Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer 1997;75 (8):1111-1118

11 Qiao L et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995;1258:215 -223

12 FitzGerald GA et al. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345 (6):433-442

13 Jones DA et al. Molecular Cloning of Human Prostaglandin Endoperoxide Synthase Type II and Demonstration of Expression in Response to Cytokines. J Biol Chem 1993;268 (12):9049-9054

14 Chandrasekharan NV et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA. 2002 Oct 15;99 (21):13926-31. Epub 2002 Sep 19.

15 Warner TD et al. Nonsteroidal drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proc Natl Acad Sci USA June 1999;96:7563 -7568

16 Phillips RK et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002 Jun;50 (6):857-860

17 Sano H et al. Expression of Cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 1995;55:3785-3789

18 Hida T et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998;58 (17):3761-3764

19 Achiwa H et al. Prognostic Significance of elevated Cyclooxygenase 2 expression in primary resected lung adenocarcinomas. Clin Cancer Res 1999;5 (5):1001-1005

20 Gupta S et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42 (1):73-78

21 Yip-Schneider et al. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21 (2):139-146

22 Lim HY et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res 2000;6 (2):519-525

23 Chan G et al. Cyclooxygenase-2 expression is upregulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59 (5): 991-994

24 Oshima M et al. Suppression of Intestinal Polyposis in APC Knockout Mice by Inhibition of Cyclooxygenase-2 (COX-2). Cell 1996 Nov 29;87:803-809

25 Liu CH et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001 May 25;276 (21):18563-18569

26 Uefuji K et al. Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. J Surg Oncol 2001 Jan;76 (1):26-30

27 Masunaga R et al. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000;6(10):4064-4068

28 Khuri FR Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non.small cell lung cancer. Clin Cancer Res 2001;7( 4):861-867

29 Takahashi T et al. Increased expression of COX-2 in the development of human lung cancers. J Environ Pathol Toxicol Oncol 2002;21(2):177-181

30 Tsujii M et al. Alterations in cellular ahesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83(3):493-501

31 Uefuji K et al. Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin Cancer Res 2000;6(1):135-138

32 Rigas B et al. Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 1993;122(5):489-490

33 Sheng H et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998; 58(2):362-366

34 Chan TA et al. Mechanisms underlying nonsteroidal anti-inflammatory drug-mediated apoptosis. Proc Natl Acad Sci, USA 1998 ; 95:681 -686

35 Roberts RA et al. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPAR alpha). Carcinogenesis 1998;19:43-48

36 Tsubouchi Y et al. Inhibition of human lung cancer growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun 2000;270:400-405

37 Gupta R et al. Prostacylin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci 2000;97:13275 -13280

38 He TC et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-345

39 Liu XH et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998;58(19):4245-4249

40 Hsu A et al. The Cyclooxygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2. J Biol Chem 2000;275(15):11397-11403

41 Cao Y et al. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 2000;97:11280-11285

42 Scorrano L et al. Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha apoptotic signaling. J Biol Chem 2001;276:12035 -12040

43 Steele VE et al. Potential use of lipoxygenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs 2000;9:2121-2138

44 Chang HC et al. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncology Reports 2001;8:1321 -1325

45 McGinty A et al. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cell. J Biol Chem 2000;275(16):12095-12101

46 Chang YW et al. Cyclooxygenase 2 promotes cell survival by stimulation of dynein light chain expression and inhibition of neuronal nitric oxide synthase activity. Mol Cell Biol 2000 ; 20(22):8571-8579

47 Gilhooly EM et al. The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 1999;15(2):267-270

48 Majima M et al. Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol 2000;130(3):641-649

49 Tsujii M et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93(5):705-16

50 Takaoka Y, Niwa S, Nagai H. Interleukin-1beta induces interleukin-6 production through the production of prostaglandin E(2) in human osteoblasts, MG-63 cells. J Biochem (Tokyo) 1999;126(3):553-8

51 Nguyen M et al. Receptors and signaling mechanisms required for prostaglandin E2-mediated regulation of mast cell degranulation and IL-6 production. J Immunol 2002;169(8):4586-93

52 Huang SP et al. Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma. J Gastroenterol Hepatol 2002 Nov;17(11):1165-9

53 Daniel TO et al. Thromboxan A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 1999;59(18):4574-4577

54 Tsujii M et al. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94(7):3336-40

55 Nelson AR et al. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000;18:1135 -1149

56 Kambayashi T et al. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derived prostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol 1995;154(7):3383-3390

57 Eling TE et al. Prostaglandin H synthase and xenobiotic oxidation. Annu Rev Pharmacol Toxicol 1990; 30: 1-45

58 Elder DJE et al. Apoptosis induction and Cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the Cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000;86:553-560

59 Rhonda F et al. Selective Inhibition of Cyclooxygenase-2 Suppresses Growth and Induces Apoptosis in Human Esophageal Adenocarcinoma Cells. Cancer Res 2000;60:5767 -5772

60 Ming Li et al. Induction of Apoptosis by cyclooxygenase-2 inhibitor NS-398 through a cyctochrome c-dependent pathway in esophageal cancer cells. Int J Cancer 2001;93:218-223

61 Hida T et al. Cyclooxygenase-2 Inhibitor Induces Apoptosis and Enhances Cyctotoxicity of Various Anticancer Agents in Non-Small Cell Lung Cancer Cell Lines. Clin Cancer Res 2000;6:2006-2011

62 Uefuji K et al. Induction of apoptosis by JTE-522, a specific cyclooxygenase-2 inhibitor, in human gastric cancer cell lines. Anticancer Res 2000;20 (6B):4279-4284

63 Chan TA. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol 2002;3:166 -173

64 Abiru S et al. Aspirin and NS-398 Inhibit Hepatocyte Growth Factor-Induced Invasiveness of Human Hepatoma Cells. Hepathology 2002;35:1117 -1124

65 Williams CS et al. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia 2001;3(5):428-436

66 Hida T et al. Non-small cell lung cancer cyclooxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res 1998;18(2A):775-782

67 Bae SH et al. Expression of Cyclooxygenase-2 (COX-2) in Hepatocellular Carcinoma and Growth Inhibition of Hepatoma Cell Lines by a COX-2 Inhibitor, NS-398. Clin Cancer Res 2001;7:1410-1418

68 Hanif R et al. Effects of nonsteroidal anti-inflammatpry drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52(2):237-245

69 Piazza GA et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997 Jul 15;57(14):2909-2915

70 Tegeder I et al. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15: 2057-2072

71 Sovak MA et al. Abberant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer . J Clin Invest 1997;100(12):2952-2960

72 Yamamoto Y et al. Sulindac inhibits activation of NFκB pathway. Biochem Pharmacol 1999;274(38):27307-27314

73 Grilli M et al. Neuroprotection by aspirin and sodium salicylate through blockade of NFκB activation. Science 1996;274:1383-1385

74 Murono S et al. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 2000;60:2555-2561

75 Yoshizaki T et al. The expression of matrix metalloproteinases 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci 1998;95:3621 -3626

76 Stark LA et al. Aspirin-induced activation of the NF-κB signaling pathway: a novel mechanism for Aspirin-mediated apoptosis in colon cancer cells. FASEB J. 2001;7:1273-1275

77 Jones R et al. Protein kinase B regulates T lymphoczyte survival, nuclear factor kappaB activation, and Bcl- X( L) levels in vivo. J Exp Med 2000;191:1721 -134

78 He TC et al. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999;99:335-345

79 Su CG et al. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104(4):383-389

80 Li H et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan recptor TR3. Science 2000;289:1150-1164

81 Kang H et al. Transcriptional induction of Nur77 by indomethacin that results in apoptosis of colon cancer cells. Biol Pharm Bull 2000;23:815 -819

82 Jemal A et al. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23-47

83 Robert Koch-Institut: Publikation "Entwicklung der Überlebensraten von Krebspatienten in Deutschland" 1999

84 Klimp A et al. Expression of Cyclooxygenase-2 and Inducible Nitric Oxide Synthase in Human Ovarian Tumors and Tumor-associated Macrophages. Cancer Res 2001 Oct1;61:7305 -7309

85 Ferrandina G et al. Cycloxygenase-2 (COX-2), Epidermal Growth Factor Receptor (EGFR), and Her-2/neu Expression in Ovarian Cancer. Gynecologic Oncology 2002;85:305 -310

86 Fairfield KM et al. Aspirin, other NSAIDs, and ovarian cancer risk (United States). Cancer Causes Control 2002 Aug;13(6):535-42

87 Cramer DW et al. Over the counter analgesics and risk of ovarian cancer. Lancet 1998;351(9096):104-107

88 Akhmedkhanov A et al. Aspirin and epithelial ovarian cancer. Prev Med 2001;33(6):682-687

89 Moysich KB et al. Regular use of analgesic drugs and ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2001;10(8):903-6

90 Tavani A et al. Aspirin and ovarian cancer: an Italian case-control study. Ann Oncol 2000; 11(9):1171-3

91 Rodriguez-Burford C et al. Effects of Nonsteroidal Anti-inflammatory Agents (NSAIDs) on Ovarian Carcinoma Cell Lines: Preclinical Evaluation of NSAIDs as Chemopreventive Agents. Clin Cancer Res 2002;8:202 -209

92 Cullen BR. RNA interference: antiviral defense and genetic tool. Nature Immunol 2002;3(7):597-599

93 Elbashir SM et al. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26(2):199-213

94 Elbashir SM et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411(6836):494-498

95 Carsten Denkert, Antje Fürstenberg, Peter Daniel, Ines Koch, Martin Köbel, Wilko Weichert, Antje Siegert and Steffen Hauptmann. Induction of GO/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene. 2003 Nov 27;22(54):8653-61

96 Nicoletti I et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Meth 1991;139:271 -279

97 Sachs L. Angewandte Statistik 9.Aufl. Springer-Verlag Berlin Heidelberg 1999:360-363

98 Lord E. The use of the range in place of the standard deviation in the t-test. Biometrica 1947;34:41 -67, Tab.10

99 Munkarah AR et al. Effects of Prostaglandin E2 on Proliferation and Apoptosis of Epithelial Ovarian Cancer Cells. J Soc Gynecol Investig 2002;9:168-73

100 Toyoshima T et al. Inhibitor of cyclooxygenase-2 induces cell-cycle arrest in the epithelial cancer cell line via up-regulation of cyclin dependent kinase inhibitor p21. Br J Cancer 2002;86:1150 -1156

101 Hung WC et al. Induction of p27KIP1 as a Mechanism Underlying NS398-Induced Growth Inhibition in Human Lung Cancer Cells. Mol Pharmacol 2000;58:1398 -1403

102 Yip-Schneider M et al. Cell Cycle Effects of Nonsteroidal Anti-Inflammatory Drugs and Enhanced Growth Inhibition in Combination with Gemcitabine in Pancreatic Carcinoma Cells. J Pharmacol Exp Ther 2001;298(3):976-985

103 Subbegowda R and Frommel TO. Aspirin Toxicity for Human Colonic Tumor Cells Results from Necrosis and Is Accompanied by Cell Cycle Arrest. Cancer Res 1998;58:2772-2776

104 Hurwitz A et al. Interleukin-1 is both morphogenic and cytotoxic to cultured ovarian cells: obligatory role for heterologous, contact-independent cell-cell interaction. Endocrinology 1992 Oct;131(4):1643-1649

105 Rieder J et al. Nitric oxide-dependent apoptosis in ovarian carcinoma cell lines. Gynecol Oncol 2001;82(1):172-176

106 Verschraegen CF et al. Effects of interleukin-1 alpha on ovarian carcinoma patients with recurrent disease. Eur J Cancer. 1996 Aug;32A(9):1609-1611

107 Windbichler GH et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000;82(6):1138-1144

108 Song X et al. Cyclooxygenase-2, Player or Spectator in Cyclooxygenase-2 Inhibitor-Induced Apoptosis in Prostate Cancer Cells. J National Cancer Institute 2002;94(8):585-591

109 Sherr CJ. Cancer Cell Cycle. Science. 1996;274(5293):1672-7

110 Smith ML et al. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanism of action. European Journal of Cancer 2000;36:664 -674

111 Moalic-Juge S et al. The anti-apoptotic property of NS-398 at high dose can be mediated in part through NF- κ B activation, hsp70 induction and a decrease in caspase-3 activity in human osteosarcoma cells. Int J Oncol 2002;20:1255-1262

112 Husain S et al. MAPK (ERK2) kinase – a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sciences 2001;69:3045-3054

113 Trifan OC et al. Overexpression of Cyclooxygenase-2 Induces Cell Cycle Arrest. J Biol Chem 1999;274(48):34141-34147

114 Zahner G et al. Cyclooxygenase-2 overexpression inhibits platelet-derived growth factor induced mesangial cell proliferation through induction of the tumor suppressor gene p53 and the cyclin-dependent kinase inhibitors p21waf-1/cip-1 and p27kip-1. J Biol Chem 2002;277(12):9763-9771

115 Miwa Y et al. 15-Deoxy- Delta( 12,14)-prostaglandin J(2) induces G(1) arrest and differentiation marker expression in vascular smooth muscle cells. Mol Pharmacol 2000;58(4):837-844

116 Inoue H et al. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 2000;275(36):28028-28032

117 Moalic S et al. Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 2001;18(3):533-540

118 Tanaka A et al. Up-regulation of cyclooxygenase-2 by inhibition of cyclooxygenase-1: a key to nonsteroidal anti-inflammatory drug-induced intestinal damage. J Pharmacol Exp Ther 2002;300(3):751-761

119 Law BK et al. Salicylate-induced Growth Arrest Is Associated with Inhibition of p70s6k and Down-regulation of c-Myc, Cyclin D1, Cyclin A, and Proliferating Cell Nuclear Antigen. J Biol Chem 2000;278(49):38261- 38267

120 Weiss H et al. Inhibition of store-operated Calcium entry contributes to the anti-proliferative effect of Non-steroidal Anti-Inflammatory Drugs in human colon cancer cells. Int J Cancer 2001;92:877-882

121 Swamy MV et al. Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: A novel approach in developing effective chemopreventive regimens. Int J Oncol 2002;20:753-759

122 Pyo H et al. A Selective Cyclooxygenase-2 Inhibitor, NS-398, Enhances the Effect of Radiation in Vitro and in Vivo preferentially on the Cells That Express Cyclooxygenase-2. Clin Cancer Res 2001, Oct,7:2998 -3005

123 Zhang Z et al. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 2000 Jun;118(6):1012-1017

124 Camandola S et al. Pro-apoptotic action of PAR-4 involves inhibition of NF-kappaB activity and suppression of BCL-2 expression . J Neurosci Res 2000 Jul 15;61(2):134-139

125 Tamatani M et al. Tumor necrosis factor induces BCL-2 and BCL-x expression through NfkappaB activation in primary hippocampal neurons . J Biol Chem 1999 Mar;274(13):8531-8538


© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.
DiML DTD Version 2.0Zertifizierter Dokumentenserver
der Humboldt-Universität zu Berlin
HTML-Version erstellt am:
17.01.2005